IRON DEFICIENCY ANAEMIA IN ACTIVE PULMONORY TUBERCULOSIS PATIENTS: UNDERSTANDING THE INTERPLAY AND IMPLICATIONS FOR MANAGEMENT

Iron deficiency anemia (IDA) is a common comorbidity in individuals with active pulmonary tuberculosis (PTB) and also it has negative impact on its treatment, yet its clinical significance and management remain underexplored.This article aims to elucidate the intricate relationship between iron status and pulmonary tuberculosis, examining its prevalence, etiology, and clinical implications.IDA in PTB patients can exacerbate symptoms such as fatigue and dyspnea, impairing quality of life and potentially hindering treatment outcomes.The underlying mechanisms linking IDA to PTB pathogenesis, including inflammation-induced hepcidin upregulation and altered iron metabolism, are discussed.Furthermore, challenges in diagnosing and managing IDA in PTB patients, including the limitations of traditional laboratory markers and concerns regarding iron supplementation, are addressed.Strategies for optimizing diagnostic approaches and tailoring iron supplementation regimens to mitigate potential adverse effects while ensuring treatment efficacy are proposed.Finally, the importance of a multidisciplinary approach involving collaboration between pulmonologists, hematologists, and infectious disease specialists in managing IDA in PTB patients is emphasized.Enhancing our understanding of IDA in the context of PTB is crucial for improving clinical outcomes and reducing the burden of disease in this vulnerable population.